Invitrogen™ CD79a Monoclonal Antibody (24C2.5), eBioscience™, Invitrogen™

Mouse Monoclonal Antibody

Supplier:  Invitrogen™ 14079182

Catalog No. 50-127-05

Description

Description: This 24C2.5 monoclonal antibody reacts with the intracellular tail of mouse CD79a (also known as Ig alpha or mb-1), a signaling component of the B cell receptor (BCR). CD79a heterodimerizes with CD79b (Ig beta, B29), and together with surface Ig, make up the BCR. Both CD79 subunits consist of a single extracellular Ig domain, a transmembrane domain, and an intracellular signaling domain. CD79a is expressed almost exclusively on B cells, as well as in most B lineage acute lymphoblastic leukemias. The cytoplasmic domain of CD79a contains immunoreceptor tyrosine-based activation motifs (ITAMs), which constitute the signal transducing portions of the BCR. Tyrosine phosphorylation of these ITAMs by Syk and Lyn initiates numerous signaling cascades, resulting in B cell activation, proliferation, and differentiation. Applications Reported: This 24C2.5 antibody has been reported for use in immunoblotting (WB). Applications Tested: This 24C2.5 antibody has been tested by western blot of reduced mouse spleen lysates. This can be used at 1-10 μg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

CD79a is a disulphide-linked heterodimer that includes B29 (CD79b) polypeptide. CD79a is a B lymphocyte antigen receptor with an antigen-specific surface component Ig (immunoglobulin) that associates with Ig-alpha and Ig-beta, necessary elements for the expression and function of the B-cell antigen receptor. CD79a first appears at pre-B cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Diseases associated with CD79a include Agammaglobulinemia 3 and Agammaglobulinemia, Non-Bruton type.

Specifications

• Antigen: CD79a
• Classification: Monoclonal
• Concentration: 0.5 mg/mL
• Formulation: PBS with 0.09% sodium azide; pH 7.2
• Gene Accession No.: P11911, P11912
• Gene Symbols: CD79A
• Purification Method: Affinity Chromatography
• Regulatory Status: RUO
• Gene ID (Entrez): 12518, 973
• Content And Storage: 4°C
• Form: Liquid

• Applications: Immunohistochemistry, Western Blot
• Clone: 24C2.5
• Conjugate: Unconjugated
• Gene: CD79A
• Gene Alias: B-cell antigen receptor; B-cell antigen receptor complex-associated protein alpha chain; B-cell antigen receptor complex-associated protein alpha chain-like; CD79; CD79a; CD79A antigen (immunoglobulin-associated alpha); CD79a molecule; CD79a molecule, immunoglobulin-associated alpha; CD79A protein; CD79-alpha protein; EGK_10665; Ig alpha; IGA; Igalpha; ig-alpha; immunoglobulin-associated alpha; LOC100913063; Ly54; Ly-54; MB1; MB-1; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; surface IgM-associated protein
• Host Species: Mouse
• Quantity: 100 μg
• Primary or Secondary: Primary
• Target Species: Human, Mouse
• Product Type: Antibody
• Isotype: IgG1 κ

For Research Use Only.